Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2785-2790

  Perez Soler, R ^a   Glisson, B S ^a   Lee, J S ^a   Fossella, F V ^a   Murphy, W K ^a   Shin, D M ^a   Hong, W K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0029758947     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2785     Document Type: Article

References (39)

1. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375, 1989
2. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
3. Creemerst GJ, Lund B, Verweij J: Topoisomserase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
4. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
5. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
6. Eng WK, McCabe FL, Tan KB, et al: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471-480, 1990
7. Tanizawa A, Pommier Y: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52:1848-1854, 1992
8. Tanizawa A, Fujimori A, Fujimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994
9. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
10. Kudelka A, Edwards C, Freedman B, et al: An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 12:259,1993 (abstr)
11. Schiller JH, Kim K, Johnson D, et al: Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13:330, 1994 (abstr)
12. Wanders J, Ardizzoni A, Hansen HH, et al: Phase II study of topotecan in refractory and sensitive SCLC. Proc Am Assoc Cancer Res 36:1415, 1995 (abstr)
13. Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of TPT in NSCLC previously untreated with chemotherapy. J Clin Oncol 14:503-513, 1996
14. Robert F, Wheeler RH, Molthrop DC, et al: Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 13:281, 1994 (abstr)
15. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993
16. Lynch TJ Jr, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347-352, 1994
17. Sugarman SM, Ajani JA, Daugherty K, et al: A phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Am Soc Clin Oncol 13:224, 1994 (abstr)
18. Creemers GJ, Wanders J, Calabresi F, et al: Eighth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands, March 15-18, 1994, p 191
19. Postmus PE, Berendsen HH, Zandwijk NV, et al: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. J Cancer Clin Oncol 23:1409-1411, 1987
20. Batist G, Carney DN, Cowan KH, et al: Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: Clinical trial and in vitro correlates. J Clin Oncol 4:982-986, 1986
21. Vincent M, Evans B, Smith I: First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 21:45-48, 1988
22. Einhorn LH, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 17:32-25, 1990
23. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
24. Shepherd FA, Evans WK, MacCormick R, et al: Cyclophosphamide, doxorubicin and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 71:941-944, 1987
25. Faylona EA, Loehrer PJ, Ansari R, et al: Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: A Hoosier Oncology Group trial. J Clin Oncol 13:1209-1214, 1995
26. Lopez JA, Mann J, Grapski RT, et al: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 69:369-371, 1985
27. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small cell lung cancer. J Clin Oncol 3:65-71, 1985
28. Issell BF, Einhorn LH, Comis RL, et al: Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat Rep 69:127-128, 1985
29. Kauffman SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
30. Bertrand R, O'Connor PM, Kerrigan D, et al: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma, HT-29 cells. Eur J Cancer (in press)
31. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
32. Evans WK, Fields R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451-458, 1987
33. Fukuoka M, Furuse K, Saijo N, et al: Randomized comparison of cyclophosphamide. doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
34. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin. and vincristine versus etoposide and cisplatin versus alternation of these two regiments in extensive small cell lung cancer: A phase III trial of the Southestern Cancer Study Group. J Clin Oncol 10:282-291, 1992
35. Niimi S, Nakagawa K, Sugimoto Y, et al: Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52:328-333, 1992
36. van der Graaf WTA, Mulder NH, Meijer C, et al: The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multi-drug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. Cancer Chemother Pharmacol 35:345-348, 1995
37. Poupon MF, Arvelo F, Goguel AF, et al: Response of small-cell lung cancer xenografts to chemotherapy: Multidrug resistance and direct clinical correlates. J Natl Cancer Inst 85:2023-2029, 1993
38. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992
39. Masuda N, Fukuoka M, Kusunoki T, et al: CPT-11 : A new derivative of campothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992